(4r)-3-[(2s,3s)-3-[[(2s)-2-[[(2s)-2-Azanyl-2-Phenyl-Ethanoyl]amino]-3,3-Dimethyl-Butanoyl]amino]-2-Hydroxy-4-Phenyl-Butanoyl]-5,5-Dimethyl-N-(2-Methylpropyl)-1,3-Thiazolidine-4-Carboxamide | 1040199-08-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (4r)-3-[(2s,3s)-3-[[(2s)-2-[[(2s)-2-Azanyl-2-Phenyl-Ethanoyl]amino]-3,3-Dimethyl-Butanoyl]amino]-2-Hydroxy-4-Phenyl-Butanoyl]-5,5-Dimethyl-N-(2-Methylpropyl)-1,3-Thiazolidine-4-Carboxamide
• 英文别名: (4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-N-(2-methylpropyl)-1,3-thiazolidine-4-carboxamide
• CAS: 1040199-08-3
• 化学式: C₃₄H₄₉N₅O₅S
• 分子量: 639.86
• InChiKey: GKUGZHJDSRCEKG-APNLASKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (4r)-3-[(2s,3s)-3-[[(2s)-2-[[(2s)-2-Azanyl-2-Phenyl-Ethanoyl]amino]-3,3-Dimethyl-Butanoyl]amino]-2-Hydroxy-4-Phenyl-Butanoyl]-5,5-Dimethyl-N-(2-Methylpropyl)-1,3-Thiazolidine-4-Carboxamide 、 3,3-二甲基-1-丁酸 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以58%的产率得到(4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-(3,3-dimethylbutanoylamino)-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-N-(2-methylpropyl)-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties

  摘要：

  The causative agent behind adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy is the human T-cell leukemia virus type 1 (HTLV-I). Tetrapeptidic HTLV-I protease inhibitors were designed on a previously reported potent inhibitor KNI-10516, with modifications at the P-3-cap moieties. All the inhibitors showed high HIV-1 protease inhibitory activity (over 98% inhibition at 50 nM) and most exhibited highly potent inhibition against HTLV-I protease (IC50 values were less than 100 nM). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.03.055
• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 (4r)-3-[(2s,3s)-3-[[(2s)-2-[[(2s)-2-Azanyl-2-Phenyl-Ethanoyl]amino]-3,3-Dimethyl-Butanoyl]amino]-2-Hydroxy-4-Phenyl-Butanoyl]-5,5-Dimethyl-N-(2-Methylpropyl)-1,3-Thiazolidine-4-Carboxamide
  参考文献：
  名称：

  Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors

  摘要：

  The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-1). We recently unveiled a potent hexapeptidic HTLV-1 protease inhibitor, KNI-10166, composed mostly of natural amino acid residues. Herein, we report the derivation of potent tetrapeptidic inhibitor KNI-10516, possessing only non-natural amino acid residues. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.066

文献信息

• Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties
  作者：Meihui Zhang、Jeffrey-Tri Nguyen、Henri-Obadja Kumada、Tooru Kimura、Maosheng Cheng、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmc.2008.03.055

  日期：2008.5

  The causative agent behind adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy is the human T-cell leukemia virus type 1 (HTLV-I). Tetrapeptidic HTLV-I protease inhibitors were designed on a previously reported potent inhibitor KNI-10516, with modifications at the P-3-cap moieties. All the inhibitors showed high HIV-1 protease inhibitory activity (over 98% inhibition at 50 nM) and most exhibited highly potent inhibition against HTLV-I protease (IC50 values were less than 100 nM). (C) 2008 Elsevier Ltd. All rights reserved.
• Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
  作者：Jeffrey-Tri Nguyen、Meihui Zhang、Henri-Obadja Kumada、Ayako Itami、Keiji Nishiyama、Tooru Kimura、Maosheng Cheng、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2007.10.066

  日期：2008.1

  The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-1). We recently unveiled a potent hexapeptidic HTLV-1 protease inhibitor, KNI-10166, composed mostly of natural amino acid residues. Herein, we report the derivation of potent tetrapeptidic inhibitor KNI-10516, possessing only non-natural amino acid residues. (C) 2007 Elsevier Ltd. All rights reserved.